Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen de la Victoria (16)

2024

  1. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2021

  1. Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study

    Journal of Clinical Oncology, Vol. 39, Núm. 30, pp. 3391-3402

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

2020

  1. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

    Investigational New Drugs, Vol. 38, Núm. 2, pp. 457-467

  2. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 759-771

2019

  1. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

    Lung Cancer, Vol. 136, pp. 74-79

  2. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  4. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

    Journal of Thoracic Oncology, Vol. 14, Núm. 10, pp. 1828-1838

2017

  1. A consensus statement on the gender perspective in lung cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

  2. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

2013

  1. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 977-984

2011

  1. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

    Lung Cancer, Vol. 72, Núm. 1, pp. 84-91

2009

  1. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

    Clinical and Translational Oncology

2008

  1. Can we customize chemotherapy? individualizing cytotoxic regimens in advanced non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 9, Núm. SUPPL. 2

2003

  1. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy

    Cancer, Vol. 97, Núm. 9, pp. 2180-2186